Zentalis Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zentalis Pharmaceuticals Inc (ZNTL) have crossed above the average analyst 12-month target price of $73.00, changing hands for $73.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.